Search results for " hepatitis"

showing 10 items of 546 documents

Clinical significance of autoantibodies to soluble liver antigen in autoimmune hepatitis.

1999

Abstract Background/Aims: Classification of autoimmune hepatitis (AIH) into different subgroups according to autoantibody status has been proposed: type I (ANA/SMA), type II (LKM-1) and type III (anti-SLA). However, whether type III AIH forms a clinically distinct disease entity remains controversial. The aim of this study was to evaluate the subclassification of AIH into ANA/SMA and anti-SLA positive patients with regard to clinical, biochemical and histologic differences. Methods: Ninety-seven consecutive patients with a well-documented long-term course of AIH with ANA/SMA and/or anti-SLA autoantibodies were studied. Clinical, biochemical and histological features of patients with ANA/SMA…

AdultMaleAnti-nuclear antibodyHLA-DR3Autoimmune hepatitisAutoantigensAutoimmune DiseasesHepatitisimmune system diseasesmedicineHumansClinical significanceAutoantibodiesAutoimmune diseaseHepatitisImmunosuppression TherapyHepatologybusiness.industryfungiAutoantibodyMuscle SmoothMiddle Agedmedicine.diseaseSMA*PrognosisAntibodies AntinuclearImmunologyFemalebusinessJournal of hepatology
researchProduct

Individual and common antigen-recognition sites of liver-derived T cells in patients with autoimmune hepatitis.

2003

Autoimmune hepatitis (AIH) is characterized by dense T-cell infiltrations in the liver tissue, but little is known how T cells influence the pathogenesis. To address this question, the distribution of T-cell receptor variable beta-chain (TCR Vbeta) transcripts of peripheral blood and liver-infiltrating T cells from previously untreated patients with newly diagnosed acute exacerbated AIH was investigated. Furthermore, the lengths and sequences of complementary-determining region 3 (CDR3) were studied. Reverse transcriptase-polymerase chain reaction (RT-PCR) analysis and CDR3 spectratyping revealed multiple clonal expansions of liver-infiltrating T cells but not peripheral T cells within vari…

AdultMaleBiopsyT-LymphocytesImmunologyMolecular Sequence DataReceptors Antigen T-CellEpitopes T-Lymphocytechemical and pharmacologic phenomenaInflammationAutoimmune hepatitisBiologyCDR3 SpectratypingEpitopePathogenesismedicineHumansAmino Acid SequenceRNA MessengerReceptorAgedBase SequenceReverse Transcriptase Polymerase Chain ReactionT-cell receptorhemic and immune systemsGeneral MedicineMiddle Agedmedicine.diseaseComplementarity Determining RegionsClone CellsHepatitis AutoimmuneGene Expression RegulationImmunologyFemalemedicine.symptomNested polymerase chain reactionScandinavian journal of immunology
researchProduct

Actin is a target antigen of anti-neutrophil cytoplasmic antibodies (ANCA) in autoimmune hepatitis type-1.

1997

Abstract Background/Aim: Anti-neutrophil cytoplasmic antibodies (ANCA) are a group of autoantibodies first associated with Wegener's granulomatosis and microscopic polyangiitis. The signifiance of ANCA in autoimmune hepatitis remains uncertain; the nature of the antigen or antigens has not been defined yet. The purpose of this study was to identify the target antigen of ANCA in patients with autoimmune hepatitis. Method/Results: Sera from 32 type-1 autoimmune hepatitis patients were used in the present study. ANCA were detected in 24 of 32 sera (75%). A diffuse cytoplasmic staining pattern (C-ANCA) was detected in 14 patients; the P-ANCA pattern was observed in 10 patients. An extract of hu…

AdultMaleBlotting WesternEnzyme-Linked Immunosorbent AssayAutoimmune hepatitisTropomyosinMyosinsAntibodies Antineutrophil CytoplasmicAutoimmune DiseasesHepatitisAntigenmedicineHumanscardiovascular diseasesAntigensFluorescent Antibody Technique IndirectAnti-neutrophil cytoplasmic antibodyAgedAutoimmune diseaseHepatitisAged 80 and overHepatologybiologyAutoantibodyActomyosinBlood ProteinsMiddle Agedmedicine.diseaseActinsMolecular WeightImmunologybiology.proteinFemaleAntibodyMicroscopic polyangiitisJournal of hepatology
researchProduct

New data from the Italian National Register of Congenital Coagulopathies, 2016 Annual Survey

2018

BACKGROUND: In Italy, the National Register of Congenital Coagulopathies (NRCC) collects epidemiological and therapeutic data from patients affected by haemophilia A (HA), haemophilia B (HB), von Willebrand’s disease (vWD) and other rare coagulation disorders. Here we present data from the 2016 annual survey. MATERIALS AND METHODS: Data are provided by the Italian Haemophilia Centres, on a voluntary basis. Information flows from every Centre to a web-based platform of the Italian Association of Haemophilia Centres, shared with the Italian National Institute of Health, in accordance with current privacy laws. Patients are classified by diagnosis, disease severity, age, gender and treatment-r…

AdultMaleCanadaAdolescentAdolescent Adult Aged Blood Coagulation Factors Canada Child Coagulation Protein Disorders Factor IX Factor VIII Female France HIV Infections Hemophilia A Hemophilia B Hepatitis CHumans Infant Infant Newborn Italy Male Middle Aged Prevalence Registries Surveys and Questionnaires United Kingdom von Willebrand DiseasesHIV InfectionsCoagulation Protein DisordersHemophilia AHemophilia BFactor IXhemic and lymphatic diseasesSurveys and QuestionnairesPrevalenceHumansRegistriesChildAgedFactor VIIIInfant NewbornInfantMiddle AgedHepatitis CBlood Coagulation FactorsUnited Kingdomvon Willebrand DiseasesItalyChild PreschoolFemaleOriginal ArticleFrance
researchProduct

Predictive Scores in Primary Biliary Cirrhosis

2015

GOALS The aim of this study was to assess the long-term outcome of primary biliary cirrhosis (PBC) patients and to test the clinical value of various outcome models, such as the Mayo Risk Score (MRS), in a large single-center cohort in Germany. BACKGROUND PBC is a chronic autoimmune liver disease with a female gender predominance and a peak incidence in the fifth decade of life. PBC is characterized by portal inflammation and immune-mediated destruction of intrahepatic bile ducts in liver histology and the presence of antimitochondrial antibodies in the serum of nearly 95% of patients. In 5% to 20% of patients an overlap syndrome with autoimmune hepatitis (AIH) is diagnosed. Ursodeoxycholic…

AdultMaleCholagogues and Cholereticsmedicine.medical_specialtyPathologyAdolescentmedicine.medical_treatmentIntrahepatic bile ductsAutoimmune hepatitisLiver transplantationSeverity of Illness IndexGastroenterologyYoung AdultLiver diseasePrimary biliary cirrhosisPredictive Value of TestsInternal medicinemedicineHumansAspartate AminotransferasesChildAgedRetrospective StudiesAged 80 and overFramingham Risk ScoreLiver Cirrhosis BiliaryPlatelet Countbusiness.industryUrsodeoxycholic AcidGastroenterologyBilirubinOverlap syndromeMiddle AgedAlkaline PhosphatasePrognosismedicine.diseasedigestive system diseasesUrsodeoxycholic acidLiver TransplantationHepatitis AutoimmuneImmunoglobulin MImmunoglobulin GFemalebusinessFollow-Up Studiesmedicine.drugJournal of Clinical Gastroenterology
researchProduct

Combined Therapy with Azathioprine, Prednisolone, and Ursodiol in Patients with Primary Sclerosing Cholangitis: A Case Series

1999

No established medical therapy alters the progressive course of primary sclerosing cholangitis.To explore the potential usefulness of combined therapy with azathioprine, steroids and ursodeoxycholic acid (UDCA) in primary sclerosing cholangitis.Case series.University hospital in Mainz, Germany.15 patients with primary sclerosing cholangitis.Azathioprine (1 to 1.5 mg/kg of body weight per day), prednisolone (1 mg/kg per day initially, tapering to 5 to 10 mg per day) and UDCA (500 to 750 mg per day).Clinical and laboratory evaluation, liver biopsy, and endoscopic retrograde cholangiography (a30% change in stenosis was considered significant).After a median observation period of 41 months (ran…

AdultMaleCholagogues and Cholereticsmedicine.medical_specialtyPrednisolonemedicine.medical_treatmentCholangitis SclerosingPilot ProjectsAzathioprineAutoimmune hepatitisGastroenterologyInflammatory bowel diseasePrimary sclerosing cholangitisInternal medicineAzathioprineInternal MedicinemedicineHumansChemotherapybusiness.industryUrsodeoxycholic AcidGeneral Medicinemedicine.diseaseUlcerative colitisUrsodeoxycholic acidSurgeryRadiographyLiverPrednisoloneDrug Therapy CombinationFemalebusinessImmunosuppressive Agentsmedicine.drugAnnals of Internal Medicine
researchProduct

Concurrent autoimmune diseases in patients with autoimmune hepatitis.

2010

Although the pathomechanisms of autoimmune diseases in various organs remain unresolved, an accumulation of autoimmune diseases in individual patients has been observed. An overlap of autoimmune hepatitis (AIH) and primary biliary cirrhosis (PBC) or primary sclerosing cirrhosis has been well documented. However, the overlap of autoimmune diseases other than PBC or PSC has not yet been investigated in a large cohort.The goal of our analysis was to investigate the incidence of concurrent autoimmune diseases in patients with AIH.We analyzed our cohort of 278 patients with AIH for concurrent autoimmune diseases.A total of 111 patients (40%) were diagnosed with additional autoimmune diseases. Be…

AdultMaleCirrhosisAdolescentAutoimmune hepatitisThyroiditisAutoimmune DiseasesCohort StudiesYoung AdultPrimary biliary cirrhosisImmunopathologyMedicineHumansIn patientChildAgedAutoantibodiesHepatitisAutoimmune diseaseAged 80 and overbusiness.industryLiver Cirrhosis BiliaryGastroenterologyThyroiditis AutoimmuneMiddle Agedmedicine.diseasedigestive system diseasesHepatitis AutoimmuneImmunologyFemalebusinessFollow-Up StudiesJournal of clinical gastroenterology
researchProduct

Transforming growth factor-β1 in autoimmune hepatitis: correlation of liver tissue expression and serum levels with disease activity

1998

Abstract Background/Aims: Transforming growth factor-β 1 (TGF-β 1 ) is considered the most important mediator of hepatic fibrogenesis. At the same time, TGF-β 1 is an immunosuppressive cytokine. Development of fibrosis, often rapid, is a characteristic of autoimmune hepatitis, as is spontaneous systemic immunosuppression. The aim of our study was therefore to define the role of TGF-β 1 in autoimmune hepatitis. Methods/Results: Using the MV 1Lu bioassay, we found markedly elevated serum levels of TGF-β 1 (median 109 ng/ml) in active autoimmune hepatitis, which normalised when patients reached biochemical remission following immunosuppressive therapy (median 34 ng/ml; p =0.0001 compared to ac…

AdultMaleCirrhosisAdolescentmedicine.medical_treatmentInflammationAutoimmune hepatitismedicine.disease_causeMonocytesAutoimmunityTransforming Growth Factor betaFibrosisHumansMedicineIn Situ HybridizationAgedInflammationHepatitisHepatologybusiness.industryImmunosuppressionMiddle Agedmedicine.diseaseImmunohistochemistryHepatitis AutoimmuneCytokineLiverImmunologyBiological AssayFemalemedicine.symptombusinessBiomarkersJournal of Hepatology
researchProduct

Clinical evaluation of drug-induced hepatitis

2005

Objective: to ascertain the epidemiological characteristics, clinical symptoms, and evolution of drug-induced hepatitis over the last 22 years. Experimental design and subjects: an observational, retrospective study between 1982 and 1993, and prospective study between 1994 and 2003. All patients in our department diagnosed with having drug-induced hepatitis were studied analyzing epidemiological (age, sex, cases per year, hospitalization) and clinical features (previous liver disease, hepatic symptoms, laboratory results), and follow-up (complete recovery or chronicity). Results: a total of 61 patients were diagnosed as having drug-induced hepatitis, 26 men and 35 women (57%), mean age 52.4…

AdultMaleDrugmedicine.medical_specialtyDrug-Related Side Effects and Adverse ReactionsEpidemiologyEvolutionmedia_common.quotation_subjectLiver diseaseSex FactorsInternal medicineEpidemiologyHumansMedicineAcute hepatitisProspective cohort studyAgedRetrospective Studiesmedia_commonHepatitisClinical characteristicsbusiness.industryIncidence (epidemiology)Age FactorsGastroenterologyDrugsRetrospective cohort studyGeneral MedicineMiddle Agedmedicine.diseaseSurgeryHospitalizationSpainFemaleObservational studyChemical and Drug Induced Liver InjurybusinessRevista Española de Enfermedades Digestivas
researchProduct

Autoimmune hepatitis following Epstein-Barr virus infection

2008

We describe a case of a young man with autoimmune hepatitis (AIH) following Epstein–Barr virus (EBV) infection, in whom a long follow-up showed favourable outcome with complete clinical recovery and failure to relapse after cessation of immunosuppressive therapy. The study underlines the importance of the differential diagnosis between primary EBV associated hepatitis with features of autoimmunity, in which there is a direct pathogenetic role of the virus, and EBV related AIH, in which EBV could act as the trigger of the immune mediated damage with probable differences between the two conditions with regard to the prognosis and the responsiveness to immunosuppressive treatment. The favourab…

AdultMaleEpstein-Barr Virus InfectionsHepatitis Viral HumanAnti-Inflammatory AgentsAzathioprineDiseaseAutoimmune hepatitisSettore MED/08 - Anatomia Patologicamedicine.disease_causeMethylprednisoloneArticleVirusAutoimmunityDiagnosis Differentialimmune system diseaseshemic and lymphatic diseasesAzathioprinemedicineHumansEpstein–Barr virus infectionHepatitisbusiness.industryGeneral Medicinemedicine.diseasedigestive system diseasesHepatitis AutoimmuneLiverImmunologyDrug Therapy CombinationEBV autoimmune hepatitisDifferential diagnosisbusinessImmunosuppressive Agentsmedicine.drugCase Reports
researchProduct